Browsing by Author "Koksoy, Elif Berna"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Comparison of Gemcitabine Monotherapy with Gemcitabine and Cisplatin Combination in Metastatic Pancreatic Cancer: A Retrospective Analysis
    (2018) Ergun, Yakup; Ozdemir, Nuriye Yildirim; Guner, Ebru Karci; Esin, Ece; Sendur, Mehmet Ali; Koksoy, Elif Berna; Demirci, Nebi Serkan; Eren, Tulay; Dede, Isa; Sezer, Ahmet; Engin, Huseyin; Oksuzoglu, Berna; Yalcin, Bulent; Utkan, Gungor; Zengin, Nurullah; Urun, Yuksel; 30722120
    Purpose: Gemcitabine is among the standard first-line agents for the treatment of metastatic pancreatic cancer. However, as the median survival with gemcitabine monotherapy is 6 months, different combinations are being studied for better, prolonged survival. In this multicenter study, we aimed to compare the results of gemcitabine monotherapy with those of gemcitabine and cisplatin combination therapy as first-line treatments for metastatic pancreatic cancer. Methods: Data of 664 patients diagnosed with metastatic pancreatic cancer between January 2007 and December 2016 from seven oncology centers in Turkey were retrospectively evaluated, and 319 patients with gemcitabine alone (n=138) or gemcitabine and cisplatin combination (n=181) as first-line treatment were included. Results: The median patient age was 62 years (range 42-79), being 60 years (42-75) in the gemcitabine/cisplatin arm and 67 years (52-79) in gemcitabine alone arm. no complete response was observed in either arm, whereas partial response rates were 30.1% in gemcitabine/cisplatin arm and 15.3% in gemcitabine alone arm (p=0.001). median overall survival was 8 months (95% CI:7.7-10.2) and was significantly longer in the gemcitabine/cisplatin arm than in the gemcitabine alone arm (10 vs. 6 months, p=0.004). Conclusion: The cemcitabine and cisplatin combination therapy as first-line treatment of metastatic pancreatic cancer yields significantly prolonged survival over gemcitabine monotherapy. In patients with favorable performance conditions, the combination therapy should be preferred.
  • No Thumbnail Available
    Item
    Crizotinib Efficacy and Safety in Patients with Advanced NSCLC Harboring MET Alterations: A Real-Life Data of Turkish Oncology Group
    (2022) Gurbuz, Mustafa; Kilickap, Saadettin; Bilici, Ahmet; Karadurmus, Nuri; Sezer, Ahmet; Sendur, Mehmet Ali Nahit; Paydas, Semra; Artac, Mehmet; Fulden Yumuk, Perran; Gursoy, Pinar; Uysal, Mukremin; Senol Coskun, Hasan; Tatli, Ali Murat; Selcukbiricik, Fatih; Disel, Umut; Koksoy, Elif Berna; Guven, Deniz Can; Ugrakli, Muzaffer; Akkus, Erman; Yucel, Sebnem; Erol, Cihan; Karakaya, Serdar; Sakalar, Teoman; Khanmammadov, Nijat; Paksoy, Nail; Demirkazik, Ahmet; 36550824
    Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterations, there is limited real-life data. Aim of this study is to investigate real-life efficacy and safety of crizotinib in patients with advanced NSCLC harboring MET alterations. This was a retrospective, multicenter (17 centers) study of Turkish Oncology Group. Patients' demographic, histological data, treatment, response rates, survival outcomes, and toxicity data were collected. Outcomes were presented for the study population and compared between MET alteration types. Total of 62 patients were included with a median age of 58.5 (range, 26-78). Major histological type was adenocarcinoma, and 3 patients (4.8%) had sarcomatoid component. The most common MET analyzing method was next generation sequencing (90.3%). MET amplification and mutation frequencies were 53.2% (n = 33) and 46.8% (n = 29), respectively. Overall response rate and disease control rate were 56.5% and 74.2% in whole study population, respectively. Median progression free survival (PFS) was 7.2 months (95% confidence interval [CI]: 3.8-10.5), and median overall survival (OS) was 18.7 months (95% CI: 13.7-23.7), regardless of treatment line. Median PFS was 6.1 months (95% CI: 5.6-6.4) for patients with MET amplification, whereas 14.3 months (95% CI: 6.7-21.7) for patients with MET mutation (P = .217). Median PFS was significantly longer in patients who have never smoked (P = .040), have good performance score (P < .001), and responded to the treatment (P < .001). OS was significantly longer in patients with MET mutation (25.6 months, 95% CI: 15.9-35.3) compared to the patients with MET amplification (11.0 months; 95% CI: 5.2-16.8) (P = .049). In never-smokers, median OS was longer than smoker patients (25.6 months [95% CI: 11.8-39.3] vs 16.5 months [95% CI: 9.3-23.6]; P = .049). The most common adverse effects were fatigue (50%), peripheral edema (21%), nausea (29%) and diarrhea (19.4%). Grade 3 or 4 adverse effects were observed in 6.5% of the patients. This real-life data confirms efficacy and safety of crizotinib in the treatment of advanced NSCLC harboring MET alteration.
  • No Thumbnail Available
    Item
    Independent Prognostic Value of İnflammation in Metastatic Pancreatic Cancer
    (2018) Oksuzoglu, Berna; Esin, Ece; Koksoy, Elif Berna; Demirci, Nebi Serkan; Sendur, Mehmet Ali Nahit; Dede, Isa; Sezer, Ahmet; Karci, Ebru; Yildirim, Nuriye; Yalcin, Bulent; Utkan, Gungor; Urun, Yuksel